Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-30
Last updated

Report documents

  1. Extract of dossier assessment

    Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 792 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 792 kB, EN, not accessible)

  2. Dossier assessment

    Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

First-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma

Result of dossier assessment:
  • With Child-Pugh A or no hepatic cirrhosis: added benefit not proven
  • With Child-Pugh B: added benefit not proven

Project details

Project no.
A23-30
Commission
Commission awarded on 03.04.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-07-03.

Connected Projects

  1. Dossier assessment

    Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-29
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-98
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V

    Project no.
    A25-97
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V

    Project no.
    A25-96
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Durvalumab (gastric or gastro-oesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-96
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-87
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-86
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-138
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page